請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/32150
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳燕惠 | |
dc.contributor.author | Guann-Miaw Chou | en |
dc.contributor.author | 周冠妙 | zh_TW |
dc.date.accessioned | 2021-06-13T03:33:59Z | - |
dc.date.available | 2011-08-03 | |
dc.date.copyright | 2006-08-03 | |
dc.date.issued | 2006 | |
dc.date.submitted | 2006-07-27 | |
dc.identifier.citation | 參考文獻
1. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995;155(5):469-73. 2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. Jama 2001;285(18):2370-5. 3. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82(8A):2N-9N. 4. Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 2001;86(5):516-21. 5. Friberg J, Scharling H, Gadsboll N, Truelsen T, Jensen GB. Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study). Am J Cardiol 2004;94(7):889-94. 6. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 1987;147(9):1561-4. 7. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995;98(5):476-84. 8. Chesebro JH, Fuster V, Halperin JL. Atrial fibrillation--risk marker for stroke. N Engl J Med 1990;323(22):1556-8. 9. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22(8):983-8. 10. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98(10):946-52. 11. Wolf PA, Mitchell JB, Baker CS, Kannel WB, D'Agostino RB. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med 1998;158(3):229-34. 12. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. Jama 1994;271(11):840-4. 13. Wattigney WA, Mensah GA, Croft JB. Increased atrial fibrillation mortality: United States, 1980-1998. Am J Epidemiol 2002;155(9):819-26. 14. Wolf PA, Dawber TR, Thomas HE, Jr., Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978;28(10):973-7. 15. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131(7):492-501. 16. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154(13):1449-57. 17. Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation 2003;108(6):711-6. 18. Agarwal A, York M, Kantharia BK, Ezekowitz M. Atrial fibrillation: modern concepts and management. Annu Rev Med 2005;56:475-94. 19. Greenlee RT, Vidaillet H. Recent progress in the epidemiology of atrial fibrillation. Curr Opin Cardiol 2005;20(1):7-14. 20. Cappola AR, Fried LP, Arnold AM, et al. Thyroid status, cardiovascular risk, and mortality in older adults. Jama 2006;295(9):1033-41. 21. Squizzato A, Gerdes VE, Brandjes DP, Buller HR, Stam J. Thyroid diseases and cerebrovascular disease. Stroke 2005;36(10):2302-10. 22. McNamara RL, Tamariz LJ, Segal JB, Bass EB. Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. Ann Intern Med 2003;139(12):1018-33. 23. Olshansky B. Rate versus rhythm control strategies for AF. Curr Treat Options Cardiovasc Med 2005;7(5):371-81. 24. Wyse DG. Pharmacologic approaches to rhythm versus rate control in atrial fibrillation--where are we now? Int J Cardiol 2006;110(3):301-12. 25. Ahmad K, Dorian P. Rate control in atrial fibrillation: looking beyond the average heart rate. Curr Opin Cardiol 2006;21(2):88-93. 26. Brignole M, Menozzi C, Gasparini M, et al. An evaluation of the strategy of maintenance of sinus rhythm by antiarrhythmic drug therapy after ablation and pacing therapy in patients with paroxysmal atrial fibrillation. Eur Heart J 2002;23(11):892-900. 27. Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 2003;41(10):1690-6. 28. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000;356(9244):1789-94. 29. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347(23):1834-40. 30. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347(23):1825-33. 31. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989;1(8631):175-9. 32. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992;327(20):1406-12. 33. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991;18(2):349-55. 34. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993;342(8882):1255-62. 35. Gullov AL, Koefoed BG, Petersen P, et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med 1998;158(14):1513-21. 36. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med 1990;323(22):1505-11. 37. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991;84(2):527-39. 38. Ezekowitz MD, Falk RH. The increasing need for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. Mayo Clin Proc 2004;79(7):904-13. 39. Bungard TJ, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000;160(1):41-6. 40. Guidelines for medical treatment for stroke prevention. American College of Physicians. Ann Intern Med 1994;121(1):54-5. 41. Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest 2001;119(1 Suppl):194S-206S. 42. Prystowsky EN, Benson DW, Jr., Fuster V, et al. Management of patients with atrial fibrillation. A Statement for Healthcare Professionals. From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation 1996;93(6):1262-77. 43. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in Collaboration With the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 2001;38(4):1231-66. 44. Gorelick PB, Sacco RL, Smith DB, et al. Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. Jama 1999;281(12):1112-20. 45. Rockson SG, Albers GW. Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation. J Am Coll Cardiol 2004;43(6):929-35. 46. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):204S-33S. 47. Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):287S-310S. 48. Sjoblom L, Hardemark HG, Lindgren A, et al. Management and prognostic features of intracerebral hemorrhage during anticoagulant therapy: a Swedish multicenter study. Stroke 2001;32(11):2567-74. 49. Kucher N, Castellanos LR, Quiroz R, Koo S, Fanikos J, Goldhaber SZ. Time trends in warfarin-associated hemorrhage. Am J Cardiol 2004;94(3):403-6. 50. Ansell J, Hirsh J, Dalen J, et al. Managing oral anticoagulant therapy. Chest 2001;119(1 Suppl):22S-38S. 51. Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119(1 Suppl):8S-21S. 52. Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. Am J Health Syst Pharm 2000;57(13):1221-7; quiz 8-30. 53. Kurnik D, Loebstein R, Farfel Z, Ezra D, Halkin H, Olchovsky D. Complex drug-drug-disease interactions between amiodarone, warfarin, and the thyroid gland. Medicine (Baltimore) 2004;83(2):107-13. 54. Wittkowsky AK, Devine EB. Frequency and causes of overanticoagulation and underanticoagulation in patients treated with warfarin. Pharmacotherapy 2004;24(10):1311-6. 55. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994;120(11):897-902. 56. Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke 1995;26(8):1471-7. 57. Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med 1996;124(11):970-9. 58. Neau JP, Couderq C, Ingrand P, Blanchon P, Gil R. Intracranial hemorrhage and oral anticoagulant treatment. Cerebrovasc Dis 2001;11(3):195-200. 59. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006;151(3):713-9. 60. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998;105(2):91-9. 61. Torn M, van der Meer FJ, Rosendaal FR. Lowering the intensity of oral anticoagulant therapy: effects on the risk of hemorrhage and thromboembolism. Arch Intern Med 2004;164(6):668-73. 62. Yamaguchi T. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation : a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group. Stroke 2000;31(4):817-21. 63. Hull R, Hirsh J, Jay R, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982;307(27):1676-81. 64. Turpie AG, Gunstensen J, Hirsh J, Nelson H, Gent M. Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet 1988;1(8597):1242-5. 65. Saour JN, Sieck JO, Mamo LA, Gallus AS. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med 1990;322(7):428-32. 66. Altman R, Rouvier J, Gurfinkel E, et al. Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. J Thorac Cardiovasc Surg 1991;101(3):427-31. 67. Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003;348(15):1425-34. 68. Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003;349(7):631-9. 69. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003;349(12):1133-8. 70. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ, Vandenbroucke JP, Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995;333(1):11-7. 71. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335(8):540-6. 72. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. The European Atrial Fibrillation Trial Study Group. N Engl J Med 1995;333(1):5-10. 73. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993;69(3):236-9. 74. Azar AJ, Cannegieter SC, Deckers JW, et al. Optimal intensity of oral anticoagulant therapy after myocardial infarction. J Am Coll Cardiol 1996;27(6):1349-55. 75. Matsuyama K, Matsumoto M, Sugita T, et al. Anticoagulant therapy in Japanese patients with mechanical mitral valves. Circ J 2002;66(7):668-70. 76. Mori T, Asano M, Ohtake H, et al. Anticoagulant therapy after prosthetic valve replacement -optimal PT-INR in Japanese patients. Ann Thorac Cardiovasc Surg 2002;8(2):83-7. 77. Tangelder MJ, Algra A, Lawson JA, Hennekes S, Eikelboom BC. Optimal oral anticoagulant intensity to prevent secondary ischemic and hemorrhagic events in patients after infrainguinal bypass graft surgery. Dutch BOA Study Group. J Vasc Surg 2001;33(3):522-7. 78. Cannegieter SC, Torn M, Rosendaal FR. Oral anticoagulant treatment in patients with mechanical heart valves: how to reduce the risk of thromboembolic and bleeding complications. J Intern Med 1999;245(4):369-74. 79. Yasaka M, Minematsu K, Yamaguchi T. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Intern Med 2001;40(12):1183-8. 80. Cheung CM, Tsoi TH, Huang CY. The lowest effective intensity of prophylactic anticoagulation for patients with atrial fibrillation. Cerebrovasc Dis 2005;20(2):114-9. 81. You JH, Chan FW, Wong RS, Cheng G. Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation? Br J Clin Pharmacol 2005;59(5):582-7. 82. Yu HY, Liu CH, Chen YS, Wang SS, Chu SH, Lin FY. Relationship of international normalized ratio to bleeding and thromboembolism rates in Taiwanese patients receiving vitamin K antagonist after mechanical valve replacement. J Formos Med Assoc 2005;104(4):236-43. 83. Zellner JL, Kratz JM, Crumbley AJ, 3rd, et al. Long-term experience with the St. Jude Medical valve prosthesis. Ann Thorac Surg 1999;68(4):1210-8. 84. Vink R, Kraaijenhagen RA, Hutten BA, et al. The optimal intensity of vitamin K antagonists in patients with mechanical heart valves: a meta-analysis. J Am Coll Cardiol 2003;42(12):2042-8. 85. Butchart EG, Payne N, Li HH, Buchan K, Mandana K, Grunkemeier GL. Better anticoagulation control improves survival after valve replacement. J Thorac Cardiovasc Surg 2002;123(4):715-23. 86. Dang MT, Hambleton J, Kayser SR. The influence of ethnicity on warfarin dosage requirement. Ann Pharmacother 2005;39(6):1008-12. 87. Chenhsu RY, Chiang SC, Chou MH, Lin MF. Long-term treatment with warfarin in Chinese population. Ann Pharmacother 2000;34(12):1395-401. 88. Yu HC, Chan TY, Critchley JA, Woo KS. Factors determining the maintenance dose of warfarin in Chinese patients. Qjm 1996;89(2):127-35. 89. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003;349(11):1019-26. 90. Hylek EM, Chang YC, Skates SJ, Hughes RA, Singer DE. Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med 2000;160(11):1612-7. 91. Sun X, Hu S, Qi G, Zhou Y. Low standard oral anticoagulation therapy for Chinese patients with St. Jude mechanical heart valves. Chin Med J (Engl) 2003;116(8):1175-8. 92. Yu HY, Ho YL, Chu SH, Chen YS, Wang SS, Lin FY. Long-term evaluation of Carpentier-Edwards porcine bioprosthesis for rheumatic heart disease. J Thorac Cardiovasc Surg 2003;126(1):80-9. 93. van Doorn CA, Stoodley KD, Saunders NR, Nair RU, Davies GA, Watson DA. performance into the second decade. Eur J Cardiothorac Surg 1995;9(5):253-8. 94. Reynolds MW, Fahrbach K, Hauch O, et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest 2004;126(6):1938-45. 95. Kalra L, Yu G, Perez I, Lakhani A, Donaldson N. Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness. Bmj 2000;320(7244):1236-9. 96. Yousef ZR, Tandy SC, Tudor V, et al. Warfarin for non-rheumatic atrial fibrillation: five year experience in a district general hospital. Heart 2004;90(11):1259-62. 97. Ono A, Fujita T. Low-intensity anticoagulation for stroke prevention in elderly patients with atrial fibrillation: efficacy and safety in actual clinical practice. J Clin Neurosci 2005;12(8):891-4. 98. Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 2004;164(8):880-4. 99. Garcia D, Regan S, Crowther M, Hughes RA, Hylek EM. Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest 2005;127(6):2049-56. 100. Sanoski CA, Bauman JL. Clinical observations with the amiodarone/warfarin interaction: dosing relationships with long-term therapy. Chest 2002;121(1):19-23. 101. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. Jama 2002;287(13):1690-8. 102. Yuan HY, Chen JJ, Lee MT, et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 2005;14(13):1745-51. 103. Geisen C, Watzka M, Sittinger K, et al. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost 2005;94(4):773-9. 104. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005;106(7):2329-33. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/32150 | - |
dc.description.abstract | Warfarin屬於治療指數狹窄的藥物,需要適當的療效監測,以避免療效不足或是發生出血併發症,因此,適當的療效監測是絕對必要的。Warfarin在國外臨床使用上已經建立了使用準則:特定的適應症及其相對應的目標INR範圍。一般皆認為亞洲人較白種人不易栓塞,所以多把目標INR值降低一些;國內在臨床處置上也多維持在較低的目標INR範圍內,然而,對於國人的目標INR範圍是否不需要維持在國外準則的建議範圍之內,在兼顧療效性以及安全性下,是否維持較低的INR即可,尚未有較完整的討論。另一方面,warfarin維持劑量的高低變異極大,也是醫師開方時的一大困擾。
本研究納入民國93年1月1日至94年9月30日期間,在台大醫院內有使用warfarin的門診紀錄的患者,依照American College of Chest Physicians(ACCP)準則選取符合目標INR建議值為2-3的心房纖維顫動患者,收集病患於研究期間內的warfarin用藥紀錄、栓塞併發症或是出血併發症的紀錄、以及研究期間內所有INR檢驗值。栓塞併發症 (thromboembolism)定義為急診或是住院診斷中出現缺血性中風、暫時性腦部缺血性發作、動脈栓塞、以及心肌梗塞。重大出血併發症(major bleeding)定義為急診或是住院診斷中出現胃腸道出血或是腦部出血。病患追蹤時間起始於warfarin的第一次開方日期,終止於研究結束、停止服用warfarin或是出現併發症的診斷碼,取三者中最早出現的。INR分層為:INR<1.5, 1.5-1.9, 2.0-2.5, 2.6-3.0, 3.1-3.5, >3.5;估算暴露於各INR分層下的時間以及併發症的發生率。 本研究共收錄699位病患,總計追蹤時間為867人年。結果顯示,病患維持INR值於2-3的時間只佔了所有追蹤時間的34%,約有56%的時間是維持在INR<2。病患大部份的時間是維持在INR=1.5-3.0。為了檢測國人降低木INR 值的可行性,分析病患暴露在INR=1.5-2.5的併發症發生率(3.96%/年)是比INR<1.5(10%/年)以及INR>2.5(16.9%/年)分層下的發生率都來的低 (p=0.038)。因此,在ACCP建議目標INR=2-3的心房纖維顫動患者,維持較低的目標在1.5-2.5,是可行的。 另外,分析病患發生栓塞併發症或是出血併發症的危險因子,納入分析病患年齡、性別、合併疾病狀態,包含:高血壓、冠狀動脈疾病、糖尿病、心臟衰竭、僧帽瓣瓣膜疾病、貧血、惡性腫瘤、先前曾發生中風、暫時性腦部缺血性發作、或是胃腸道出血。冠狀動脈疾病是栓塞併發症的危險因子(odds ratio=2.17, 1.11-4.26),但是在校正過其他因素後的勝算比無統計上顯著的意義(odds ratio=1.93, 0.83-3.11)。較大的年齡,≧75歲是出血併發症的危險因子(odds ratio=3.34, 1.52 -7.36),在校正過其他因素後勝算比為3.17 (1.54-6.29)。 本研究分析病患維持劑量的預測因子,納入分析病患年齡、性別、 合併疾病狀態,包含:高血壓、冠狀動脈疾病、糖尿病、心臟衰竭、僧帽瓣瓣膜疾病、貧血、惡性腫瘤、先前曾發生中風、暫時性腦部缺血性發作、或是胃腸道出血、amiodarone平均劑量。結果顯示:年齡越大,使用的劑量越少,呈現負相關,γ=-0.32, p=0.039。 本研究提供了心房纖維顫動的國人降低目標INR至1.5-2.5的可行性,也發現年齡大於75歲的患者是出血的高危險群,以及維持劑量隨年齡增加而減少。希望有助於國人在使用warfarin的時候可以兼顧療效性與安全性,也可以提供醫師在開方時的參考資料。然而,這樣的結果無法完全解釋,國人較白種人不易栓塞,仍需要更進一步的研究。 | zh_TW |
dc.description.abstract | The pharmacokinetic profile of warfarin is complex. Monitoring is required to avoid both thromboembolic events associated with low intensity anticoagulation and hemorrhagic complications associated with high intensity. Target levels of oral anticoagulation are disease- specific and measured with the international normalized ratio (INR). To attain applicable INR values, patients are routinely monitored and their doses are adjusted when necessary. In practice, it is difficult to maintain a stable and optimal INR because of unexpected fluctuations of the INR values. This can be attributed to many factors including changes in diet, poor compliance with medication, alcohol consumption, and drug-drug interactions.
It has been suggested to keep Asian patients at a lower intensity of anticoagulation because Asians seem to be less vulnerable to thrombotic diseases than White people.Although evidence to support the practice is lacking, most clinicians are cautious to keep at a lower INR. The gudeline of the American College of Chest Physicians (ACCP) recommended the optimal INR for patients with atrial fibrillation at 2-3. However, this range for Europeans and Americans has been questioned as being excessively high for Taiwanese with atrial fibrillation. We performed a retrospective study in National Taiwan University Hospital (NTUH) on patients with atrial fibrillation taking warfarin for storke prevention from January 1, 2004,to September 30,2005.Patients were excluded if they had any a histiry of mechanical heart valve replacement before the recorded AF diagnosis because the target INR range is higher for this indication.We systemically collected the records of warfarin use, comorbid diseases, and all INR results. Thromboembolic episodes included ischemic stroke, transient ischemic attack ,arterial embolism and thrombosis and myocardial infarction .Major bleeding episodes included intracranial hemorrhage and gastrointestinal bleeding .The INR at the time of events or defined temporally related within the past 7 days of the thromboembolic and bleeding episodes were recorded. The INR range was divided into 6 categories: <1.5, 1.5-1.9, 2.0-2.5, 2.6-3.0,3.1-3.5,>3.5.The number of events was recorded for each catogories and this formed the numerator.The denominator was the summation of time each patients stayed in each category of INR.The event rate was calculated for each INR category. Six hundreds and sixty nine patients were included in the analysis , which constituted 867 patient -years. The time spent in INR=2-3 was 34%. Most time(70.8%) was spent in INR=1.5-3.0. The overall event rate was lowest in the range from 1.5-2.5(3.96%), compared to INR<1.5(10%) or INR>2.5(16.9), p=0.038. This supports the clinical feasibility of lower intensity anticoagulant therapy for Taiwanese patients with atrial fibrillation. Among these patients, coronary artery disease was a risk factor for thromboembolism in univariate analysis. However,older age(≧75 years)was a risk factor for bleeding in multivariate analysis.Among patients taking warfarin longer than 4 weeks,age correlated negatively with the maintenance dose of warfarin (γ=-0.32,p=0.004). In conclusion, our retrospective study showed that an INR between 1.5-2.5 was associated with lower complications in Taiwanese patients treated with warfarin. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T03:33:59Z (GMT). No. of bitstreams: 1 ntu-95-R93451006-1.pdf: 673966 bytes, checksum: 8f543aec7e88ce8077ec6410f6736883 (MD5) Previous issue date: 2006 | en |
dc.description.tableofcontents | 第一章 前言………………………………………………………1
第二章 文獻探討…………………………………………………3 第一節 心房纖維顫動流行病學簡介…………………………………3 第二節 心房纖維顫動患者的治療……………………………………5 一、 治療目標………………………………………………………5 二、 疾病本身的治療………………………………………………5 三、 抗凝血劑的治療地位…………………………………………7 四、 抗凝血劑的臨床使用準則……………………………………8 第三節 藥物副作用與建議處置………………………………………16 一、 相關副作用……………………………………………………16 二、 出血部位以及分類……………………………………………16 三、 出血的頻率……………………………………………………17 四、 可能影響抗凝血強度的因素…………………………………18 五、 出血併發症的預測因子………………………………………29 第四節 國內的臨床處置………………………………………………33 一、 適切的INR範圍………………………………………………33 二、 劑量投與………………………………………………………35 第三章 研究動機與目的……………………………………… 41 第四章 研究方法…………………………………………………43 第一節、資料來源…………………………………………………………43 一、 資料申請………………………………………………………43 二、 病患納入分析條件……………………………………………43 三、 病患排除分析條件……………………………………………44 第二節、資料分析…………………………………………………………44 一、 療效監測概況…………………………………………………44 二、 以內插法檢測心房纖維顫動患者維持目標INR值於1.5-2.5的可行性…………………………………………………………45 三、 探討心房纖維顫動患者發生併發症的危險因子……………54 四、 探討影響維持劑量高低的預測因子…………………………55 第三節、研究流程示意圖…………………………………………………56 第四節、統計方法…………………………………………………………57 第五章 結果………………………………………………………58 第一節、療效監測概況……………………………………………………60 一、 原始報告INR數值分佈………………………………………60 二、 INR檢測次數分佈………………………………………………60 三、 INR檢測時間間隔………………………………………………61 第二節、以內插法檢測心房纖維顫動患者維持目標INR值於1.5-2.5的可行性……………………………………………………………64 一、追蹤時間…………………………………………………………64 二、追蹤時間以INR分層計算………………………………………64 三、Warfarin使用下發生栓塞併發症……………………………66 四、Warfarin使用下發生出血併發症………………………………66 五、Warfarin使用下發生所有的併發症……………………………67 第三節、探討心房纖維顫動患者發生併發症的危險因子……………72 一、單變數分析………………………………………………………72 二、多變數分析………………………………………………………72 第四節、探討影響維持劑量高低的預測因子…………………………75 一、每日平均劑量……………………………………………………75 二、預測因子分析………………………………………………………75 第六章 討論………………………………………………………79 第一節、抗凝血的療效監測……………………………………………79 第二節、適切的INR範圍………………………………………………82 第三節、併發症的預測因子分析………………………………………89 第四節、維持劑量的預測因子…………………………………………91 第五節、研究限制………………………………………………………94 第七章 結論與未來方向…………………………………………96 參考文獻……………………………………………………………99 圖目錄 圖2-1 5個大型臨床試驗的薈萃分析結果…………………………………11 圖2-2 6個大型臨床試驗的薈萃分析結果…………………………………11 圖 2-3 服用抗凝血劑相對於控制組的比較…………………………………12 圖 2-4 藥物-藥物-疾病交互作用……………………………………………20 圖2-5 INR相對應發生缺血性中風及腦內出血的勝算比…………………31 圖2-6 不同種族間每週平均劑量……………………………………………40 圖4-1 依ACCP準則選取建議目標INR範圍為2-3的病患………………49 圖 4-2 追蹤時間以INR分層計算…………………………………………52 圖5-1 納入分析病患人數…………………………………………………59 圖5-2 原始報告INR數值分佈概況………………………………………62 圖5-3 INR檢測的次數………………………………………………………62 圖5-4 心房纖維顫動患者檢測INR的次數………………………………63 圖5-5 檢測INR的時間間隔分佈 …………………………………………63 圖5-6 追蹤時間以INR分層計算…………………………………………65 圖5-7 INR分層下的併發症發生率-I……………………………………69 圖5-8 INR分層下的併發症發生率-II…………………………………69 圖5-9 每日平均劑量………………………………………………………77 圖5-10 每日平均劑量………………………………………………………77 表目錄 表2-1 節律控制與速率控制兩組比較的臨床試驗整理……………………9 表2-2 心房纖維顫動患者初級預防中風的薈萃分析 ……………………10 表2-3 抗凝血劑的臨床使用準則 …………………………………………13 表2-4 ACCP建議抗凝血劑用在心房纖維顫動患者的中風危險因子分級以及治療準則……………………………………………………………14 表2-5 ACC/AHA/ESC 建議心房纖維顫動患者使用抗血栓劑的治療準則…15 表2-6 藥物動力學及藥效學參數 …………………………………………20 表2-7 疾病-藥物交互作用…………………………………………………21 表2-8 藥物-藥物交互作用…………………………………………………21 表2-9 食物-藥物交互作用…………………………………………………23 表2-10 文獻證實強度為Level I(為臨床試驗報告的結果)的藥物及食物…24 表2-11 藥用植物與warfarin間潛在藥物交互作用 ……………………25 表2-12 INR值升高的建議處理原則………………………………………32 表2-13 ACCP/NHLBI 建議warfarin使用於不同的適應…………………37 表2-14 人工心臟瓣膜置換於不同抗凝血強度下的併發症發生率………39 表4-1 疾病名稱與ICD-9 code對照表……………………………………47 表4-2 追蹤時間以INR 分層計算…………………………………………52 表5-1 併發症發生率………………………………………………………68 表5-2 比較併發症的發生率-I……………………………………………70 表5-3 比較併發症的發生率-II……………………………………………70 表5-4 病患特徵………………………………………………………………73 表5-5 併發症危險因子分析…………………………………………………74 表5-6 每日平均劑量 ………………………………………………………76 表5-7 預測因子的多變項迴歸分析………………………………………78 表6-1 心房纖維顫動患者的療效監測及併發症發生率…………………87 表6-2 亞洲人在不同的抗凝血強度下的相關性研究……………………88 表 6-3 每日平均劑量及預測因子分析……………………………………93 | |
dc.language.iso | zh-TW | |
dc.title | 某醫學中心服用Warfarin之心房纖維顫動患者最低有效抗凝血強度以及維持劑量之研究 | zh_TW |
dc.title | The Lowest Effective Intensity of Anticoagulation for
Patients with Atrial Fibrillation and the Predictor Factors of Maintenance Dose Requirement at a Medical Center | en |
dc.type | Thesis | |
dc.date.schoolyear | 94-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 林俊立,賴凌平 | |
dc.subject.keyword | 心房纖維顫動患,最低有效抗凝血強度,維持劑量, | zh_TW |
dc.subject.keyword | Atrial Fibrillation,The Lowest Effective Intensity of Anticoagulation,Maintenance Dose, | en |
dc.relation.page | 107 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2006-07-28 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床藥學研究所 | zh_TW |
顯示於系所單位: | 臨床藥學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-95-1.pdf 目前未授權公開取用 | 658.17 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。